Cancer Research, Statistics, and Treatment

: 2020  |  Volume : 3  |  Issue : 2  |  Page : 345-

COVID-19 in hematological malignancies

Bhausaheb Bagal, Pritesh Munot, Lingaraj Nayak 
 Department of Medical Oncology, Tata Memorial Hospital; Division of Adult Hematolymphoid, Medical Oncology, Tata Memorial Hospital and Homi Bhabha National Institute, Mumbai, Maharashtra, India

Correspondence Address:
Bhausaheb Bagal
Tata Memorial Centre and Homi Bhabha National Institute, Dr. E. Borges Road, Parel, Mumbai, Maharashtra

How to cite this article:
Bagal B, Munot P, Nayak L. COVID-19 in hematological malignancies.Cancer Res Stat Treat 2020;3:345-345

How to cite this URL:
Bagal B, Munot P, Nayak L. COVID-19 in hematological malignancies. Cancer Res Stat Treat [serial online] 2020 [cited 2020 Aug 15 ];3:345-345
Available from:

Full Text

We would like to thank Philip and Devasia [1] and Karpe and Nagvekar-Karpe [2] for their thorough and practical guidance on the management of hematological malignancies during the coronavirus disease 2019 (COVID-19) pandemic. While every passing day presents a new challenge, there are some initial insights from the early reports on infection with the severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in patients with hematological malignancies. Patients with hematological malignancies appear to be most susceptible to infection and do poorly once infected.[3],[4],[5] Additionally, the secondary bacterial infections compound the management and add to the morbidity and mortality of these patients, further jeopardizing the outcomes. This combined with the immediate requirement for highly immunosuppressive treatment in this malignancy adds complexity to the decision-making process. Certainly, intensive therapy in a SARS-CoV-2-infected patient can be risky,[6] and testing prior to the initiation of treatment seems logical. Therefore, a discussion of such an approach and their institutional practices by Philip et al. is useful.[1]

Also worrisome is the emergence of the trends in the cancer-directed treatment of these patients, where more than half of the patients did not receive the required therapy and intensive care support based on the perception of guarded outcomes.[4] The deviation in treatment, unfortunately, has both medical and medicolegal implications. The legal implications of such deviations may further be clarified by Karpeand Nagvekar-Karpe.[2]

Financial support and sponsorship


Conflicts of interest

There are no conflicts of interest.


1Philip CC, Devasia AJ. Treating hematolymphoid malignancies during COVID-19 in India: Challenges and potential approaches. Cancer Res Stat Treat 2020;3 Suppl S1:59-64.
2Karpe A, Nagvekar-Karpe S. Management of hematological malignancies during the COVID-19 pandemic. Cancer Res Stat Treat 2020;3 Suppl S1:54-8.
3He W, Chen L, Chen L, Yuan G, Fang Y, Chen W, et al. COVID-19 in persons with haematological cancers. Leukemia 2020.
4Malard F, Genthon A, Brissot E, van de Wyngaert Z, Marjanovic Z, Ikhlef S, et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant 2020.
5Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with cancer appear more vulnerable to SARS-COV-2: A multi-center study during the COVID-19 outbreak. Cancer Discov 2020. doi: 10.1158/2159-8290.CD-20-0422.
6Bansal N, Ghafur A. COVID-19 in oncology settings. Cancer Res Stat Treat 2020;3 Suppl S1:13-4.